Skip to main content

The new shares created by Fresenius AG's capital increase have met substantial demand from existing and new shareholders. Approx. 99.7 % of the subscription rights for ordinary shares and approx. 99.5 % of the subscription rights for preference shares were exercised.

Existing shareholders of Fresenius AG were offered two new ordinary shares for every nine existing ordinary shares and two new preference shares for every nine existing preference shares. The subscription prices were € 93 for each new ordinary share and € 102 for each new preference share. The subscription rights were traded from November 17 to November 28, 2005. The new shares will be included in the quotation of the existing shares of Fresenius AG at the Frankfurt, Munich and Düsseldorf stock exchanges on December 1, 2005. They have full dividend entitlement for 2005. Proceeds generated in the transaction are in excess of € 900 million.

Dr. Ulf M. Schneider, CEO of Fresenius AG: "The positive market reception of the capital increase reflects the confidence of the capital markets in Fresenius and confirms the acceptance of our strategy. We are very pleased with the success of the capital increase."

The transaction was executed by a bank consortium led by Deutsche Bank as Global Co-ordinator and Dresdner Kleinwort Wasserstein and WestLB as Joint Bookrunners.

THIS RELEASE IS FOR INFORMATION PURPOSES ONLY AND MAY NOT BE FURTHER DISTRIBUTED OR PASSED ON TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This release does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of Fresenius AG ("Fresenius") or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Fresenius or any member of its group or any commitment whatsoever. In particular, this release is not an offer of securities in the United States of America (including its territories and possessions), and securities of Fresenius may not be offered or sold in the United States of America absent registration under the Securities Act of 1933 (which Fresenius does not intend to effect) or an exemption from registration.

The information contained in this release is for background purposes only and is subject to amendment, revision and updating. Certain statements contained in this release may be statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, as well as the words "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements as a result of, among other factors, changing business or other market conditions and the prospects for growth anticipated by the management of Fresenius. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Fresenius does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release.